• A. E. Panerai
  • M. Bianchi
  • P. Ferrario
  • P. Sacerdote
Part of the Topics in Anaesthesia and Critical Care book series (TIACC)


Opioid drugs have not changed dramatically in the last 10 years and any progress is limited to a better knowledge of the characteristics of opioids as a group and of single drugs for specific properties. In conclusion, we are being helped more and more in making a choice that can best join efficacy and safety in each single therapeutic challenge that requires opioid drugs. As a matter of fact, the improvement in our use of these drugs has also suggested that they can be used safely, if necessary, for pathological conditions, previously considered not amenable to treatment with opioids, e.g. non-oncologic chronic pain. However, in this case it is even more important than in the case of oncologic pain to have a deep knowledge of each of the particular characteristics of each drug. Most of all, it is important to know the receptor specificity of each drug and its pharmacodynamic effects, also those not directly amenable to an interaction with opioid receptors [1].


Neuropathic Pain Opioid Receptor Immunosuppressive Effect Immunostimulatory Effect Opioid Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Reidme T, Pasternak G (1995) Opioid analgesics and antagonists. In: Hardman JG, Lim-bird LE (eds) The pharmacological basis of therapeutics. McGraw-Hill, New York, pp 521–555Google Scholar
  2. 2.
    Portenoy RK (1997) Current status of intrathecal therapy for nonmalignant pain management. J Pain Sympt Manag 14 (Suppl 3):l-48Google Scholar
  3. 3.
    Stein C (1995) The control of pain in peripheral tissues by opioids. N Engl J Med 332. 1685–1690PubMedCrossRefGoogle Scholar
  4. 4.
    Budd K (1996) The analgesic effect of tramadol hydrochloride when administered intraarticularly. 8th World Congress of Pain, Vancouver, 1 (A41): 229Google Scholar
  5. 5.
    Bianchi M, Brini A, Rovati L, De Giuli-Morghen C, Panerai AE (1989) Possible involvement of dynorphin rn clonidine induced analgesia. Med Sci Res 17. 351–352Google Scholar
  6. 6.
    Netzer R, Pflimlm P, Trube G (1993) Dextromethorphan blocks N-methyl-D-aspartateinduced currents and voltage-operated inward currents in cultured cortical neurons. Eur J Pharmacol 238: 209–216PubMedCrossRefGoogle Scholar
  7. 7.
    Shimoyama N, Shimoyama M, Elliott KJ, Inturrisi CE (1997) d-Methadone is antinociceptive in the rat formalin test. J Pharmacol Exp Ther 283. 648–652Google Scholar
  8. 8.
    Wilder-Smith CH, Schimke J, Osterwalder B, Senn HJ (1994) Oral tramadol, a mu opioid agonist and monoamine reuptake blocker, and morphine in strong cancer related pain Ann Oncol 5. 141–146Google Scholar
  9. 9.
    Swedberg MDB, Hellberg IB, Ask AL, Ericson AC (1997) Sameridine: assessment of physical dependence potential in mice of a novel type opioid with anaesthetic and analgesic effects. 27th Soc Neuroscience Meeting, New Orleans, 1 (A58.13): 126Google Scholar
  10. 10.
    Sacerdote P, Manfredi B, Mantegazza P, Panerai AE (1997) Antinociceptive and immunosuppressive effects of opiate drugs: a structure-related activity study. Br J Pharmacol 121: 834–840PubMedCrossRefGoogle Scholar
  11. 11.
    Manfredi B, Sacerdote P, Bianchi M, Locatelli L, Velhc-Radulovic J, Panerai AE (1993) Evidence for an opioid inhibitory effect on T cell proliferation. J Neuroimmunol 44: 4348CrossRefGoogle Scholar
  12. 12.
    Sacerdote P, Bianchi M, Manfredi B, Panerai AE (1997) Effects of tramadol on immune responses and nociceptive thresholds in mice. Pain 72: 325–330PubMedCrossRefGoogle Scholar

Copyright information

© Springer Verlag Italia, Milano 1999

Authors and Affiliations

  • A. E. Panerai
  • M. Bianchi
  • P. Ferrario
  • P. Sacerdote

There are no affiliations available

Personalised recommendations